Abstract
Purpose
To evaluate the prognostic value of preoperative plasma osteopontin (OPN) levels in patients with early stage of hepatocellular carcinoma (HCC).
Methods
Preoperative plasma levels of OPN were detected by ELISA in 68 patients with tumor-node-metastasis system stage-I of HBV-related HCC, and their association with tumor recurrence or patients’ survival was analyzed.
Results
The median plasma OPN level of patients was 82.51 ng/ml (25–75% interquartile range, 63.15–110.45 ng/ml). Plasma OPN levels in patients with tumor size ≥5 cm in diameter were significantly higher than that of patients with tumor size <5 cm in diameter (104.76 vs. 75.16 ng/ml, P = 0.003). When the 100 ng/ml was used as a cut-off value to divide the patients into two groups: the higher plasma OPN group and the lower plasma OPN group, the tumor recurrence rate of the higher plasma OPN group was significantly higher than that of the lower plasma OPN group (52.17 vs. 24.44%, P = 0.022). Meanwhile, the recurrence rate of the patients with positive alpha fetoprotein (AFP) (45.5%) was significantly higher than that of those negative AFP patients (12.5%, P = 0.006). A higher plasma OPN level was one leading independent prognostic factor for both overall survival (OS) and relapse-free survival in multivariate Cox models.
Conclusion
The preoperative plasma OPN level and serum AFP level in patients with early stage of HCC can be used as a prognostic marker for early stage of HCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M et al (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–521
Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS (1997) Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14:1581–1588
Cho H, Hong SW, Oh YJ, Kim MA, Kang ES, Lee JM et al (2008) Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 134:909–917
Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066
He J, Gu D, Wu X, Reynolds K, Duan X, Yao C et al (2005) Major causes of death among men and women in China. N Engl J Med 353:1124–1134
Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95:506–512
Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W et al (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11:4646–4652
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ et al (2003) Cancer statistics. CA Cancer J Clin 53:5–26
Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM et al (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287:1671–1679
Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS et al (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59–67
Pawlik TM, Scoggins CR, Thomas MB, Vauthey JN (2004) Advances in the surgical management of liver malignancies. Cancer J 10:74–87
Qin LX, Tang ZY (2004) Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 130:497–513
Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536
Wu IC, Wu MT, Chou SH, Yang SF, Goan YG, Lee JM et al (2008) Osteopontin expression in squamous cell cancer of the esophagus. World J Surg 32:1989–1995
Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC et al (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416–423
Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X et al (2006) The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132:709–717
Acknowledgments
This work was supported in part by China National Key Projects for Infectious Disease (2008ZX10002-021), China National Natural Science Foundation for Distinguished Young Scholars (30325041) and the China National High-tech Research and Development Program (863 Program) (2006AA02Z473), and Program of Shanghai Subject Chief Scientist (08XD1400800).
Conflict of interest statement
None declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sun, J., Xu, HM., Zhou, HJ. et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 136, 1–7 (2010). https://doi.org/10.1007/s00432-009-0629-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0629-x